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Background
METHODS
RESULTS
The high cost of prescription medications is a growing 
problem in US health care. Oncology is well acquainted with 
this problem, as the prices of new cancer drugs have been 
increasing exponentially in recent decades1. As a result of 
the increasing number of highly-priced chemotherapeutics 
combined with increasing out-of-pocket costs from higher 
deductibles and co-insurance, many cancer patients 
experience “financial toxicity” and may be unable to afford 
treatment.  
In response, many pharmaceutical companies offer 
various forms of financial assistance. These include copay 
assistance and copay coupons, direct grants to patients, 
pricing discounts, and in-kind gifts of drug supplies free of 
charge. One mechanism by which companies deliver in-kind 
gifts of drug supplies free of charge is Pharmaceutical 
Assistance Programs (PAPs). PAPs are industry-administered 
programs that provide free drugs to patients who 
demonstrate sufficient financial need. However, PAPs can be 
time-consuming, opaque, and difficult-to-navigate sources of 
assistance2. The overall scope and impact of PAPs in cancer 
care financing are unknown.
In this study, we sought to quantify and characterize 
the role of PAPs at an academically-affiliated, integrated 
health system in the state of North Carolina. 
The University of North Carolina Health Care System 
administers an institutional medication assistance program 
(MAP). Patients with potentially prohibitive drug costs are 
identified and referred to the MAP by clinical pharmacists. 
On referral, MAP specialists work to meet the financial need 
through copay assistance programs and foundational grants; 
if these sources are unavailable or insufficient, they submit 
an application to the relevant PAP for the needed drug. 
UNC MAP administrative records – which include all 
successful PAP applications – were our primary data source, 
supplemented by manual chart review to ascertain patient 
insurance type and cancer type. In our analysis we included 
PAP applications for cancer drugs, defined as anti-neoplastic 
agents and agents with non-oncologic indications given in 
the context of a cancer treatment protocol (eg, peg-
filgrastim), during 2014. 
Totals for UNC cancer patients with each cancer type, 
and patients treated with each drug, were obtained from 
codified EMR data. Total values of drugs obtained via PAPs 
were calculated by multiplying per-unit Average Wholesale 
Price (AWP) at time of application (contained in UNC MAP 
records) by quantity obtained. Missing drug quantities (5.2% 
of applications) were imputed using the amount needed for 
a single IV infusion or a 1-month pill supply. 
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Table 2 (Left): Distribution of PAP utilization 
among different cancer types during 2014. Total 
numbers for each cancer type at UNC were 
obtained by searching codified EMR data, and 
numbers for patients receiving drugs via PAPs were 
obtained from administrative records from the UNC 
medication assistance program. For each cancer 
type, the single drug with the highest total value 
obtained via PAPs across all patients was identified. 
Several drugs (such as imatinib, sorafenib, and peg-
filgrastim) were the highest-cost drug for several 
cancer types.  
Conclusions
While 40% of UNC cancer patients receiving PAP assistance were uninsured, the majority 
were insured by public or private payers (Figure 1). This study provides further evidence 
that many insured patients are unable to meet the cost-sharing requirements imposed by  
high-cost cancer drugs. 
The majority of drug value obtained via PAPs ($7,373,741 of $9,801,090, 75.2%) was for oral 
rather than intravenous drugs (Figure 2). This suggests a particular difficulty for patients 
in affording prescription cancer drugs. 
A total of 215 of 8,591 UNC cancer patients (2.5%) used PAPs to acquire one or more 
cancer drugs (not shown). Compared to a prior study of an institutional medication 
assistance program in 2006-2007 which found that 1.1% of cancer patients received PAP 
assistance3, this suggests that the need for charity drug assistance may be increasing. 
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A few, high-cost medications constituted the majority of drug value obtained by UNC 
cancer patients, particularly orally-administered “targeted” drugs. Two drugs alone –
imatinib and dasatinib – constituted $3,006,208 in value, which was 31% of total value 
across all drugs (Table 1). Patients with the cancer types that are most commonly 
treated with these drugs, such as chronic myeloid leukemia (CML) and kidney cancer, 
tended to require the most PAP assistance (Table 2). 
PAPs have opaque application and approval processes and administrative delays can 
lead to gaps in treatment. Therefore, they are not an ideal mechanism for a significant 
fraction of cancer patients to rely on in order to obtain standard-of-care treatments. 
Both improved access and reduced drug prices are required to meet this growing need. 
Cancer 
Diagnosis
Number of 
UNC 
patients 
with 
cancer 
type (% of 
total)
Number 
of 
patients 
receiving 
cancer 
drugs via 
PAP 
Percent 
of 
patients 
receiving 
cancer 
drugs via 
PAP 
Single drug 
with greatest 
retail value
Total 
retail 
value of 
drug with 
greatest 
retail 
value 
(USD)
Total retail 
value of all 
drugs 
obtained 
via PAP 
(USD)
CML 93 (1.1) 17 18.3 Imatinib 963,418 2,359,952
Kidney 277 (3.2) 10 3.6 Pazopanib 68,407 774,813
Breast 1865 (21.7) 38 2.0 Pegfilgrastim 401,972 766,824
Leukemia 276 (3.2) 9 3.3 Sorafenib 285,890 752,830
Melanoma 225 (2.6) 10 4.4 Ipilimumab 465,387 707,612
Lung 580 (6.8) 10 4.7 Crizotinib 519,715 672,064
Colorectal 439 (5.1) 20 4.6 Capecitabine 232,920 655,907
GIST 88 (1.0) 6 6.8 Imatinib 324,210 573,493
Lymphoma 719 (8.4) 20 2.8 Lenalidomide 205,542 528,543
ALL 89 (1.0) 8 9.0 Dasatinib 453,637 495,221
Myeloma 398 (4.6) 9 2.3 Lenalidomide 267,766 385,172
Sarcoma 221 (2.6) 8 3.6 Sunitinib 215,357 310,306
Prostate 539 (6.3) 7 1.3 Enzalutamide 224,139 273,739
Liver 173 (2.0) 8 4.6 Sorafenib 227,130 227,130
Head & Neck 308 (3.6) 11 3.6 Pegfilgrastim 107,192 155,893
Biliary 57 (0.7) 3 5.3 Pegfilgrastim 64,315 93,392
Gynecologic 1679 (19.5) 6 0.4 Bevacizumab 11,945 24,021
Pancreatic 104 (1.2) 4 3.8 Gemcitabine 11,408 15,308
Esophageal 61 (0.7) 3 4.9 Trastuzumab 13,381 13,800
Bladder 261 (3.0) 5 1.9 Pegfilgrastim 5,360 8,375
Other 139 (1.6) 3 2.2 Lomustine 3,826 6,694
Overall 8591 (100) 215 2.5 Imatinib 1,556,575 9,801,088
3. Felder, T. M., Lal, L. S., Bennett, C. L., Hung, F. & Franzini, L. Cancer patients’ use of pharmaceutical patient assistance programs in the 
outpatient pharmacy at a large tertiary cancer center. Community Oncol. 8, 279–286 (2011).
Table 1 (Right): Top-10 cancer drugs by greatest 
total value obtained from PAPs. Orally-
administered cancer drugs were common among 
the drugs with the highest value obtained from 
PAPs. The drug with the greatest total value 
obtained via PAPs was imatinib ($1,556,575), and 
the drug with the greatest average per-patient 
value obtained was crizotinib ($259,858).  Sub-q, 
subcutaneous; IV, intravenous. 
Figure 1 (Left): Insurance type of PAP-utilizing 
cancer patients. N = 215. Insurance type at the time 
of the PAP request (or first PAP request, for patients 
with multiple requests) was determined by manual 
chart review. Raw patient numbers are shown. 
Medicare patients were divided into those with and 
without Part D prescription drug coverage. “Dual 
eligible” refers to patients with both Medicare and 
Medicaid coverage. 
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Figure 2 (Right): Value of drug obtained from PAPs, 
by type of drug. The total value of drugs obtained 
via PAPs across all patients, USD. Non-oral drugs 
include those administered intravenously, 
subcutaneously, intramuscularly, and 
intravesicularly. Overall, UNC patients obtained a 
total value of $9,801,090 in drugs via PAPs during 
2014. Oral drugs constituted $7,373,741 (75.2%) of 
this total. 
Drug Name and 
total value rank
Route
Total 
patients 
receiving
Patients 
obtaining 
drug via 
PAP
% of 
patients 
obtaining 
drug via 
PAP
Retail value of 
drug obtained 
via PAP (USD)
Avg retail 
value per 
patient 
(USD) 
1) Imatinib Oral 84 12 14.3 1,556,575 129,715 
2) Dasatinib Oral 53 12 22.6 1,449,633 120,803 
3) Pegfilgrastim Sub-q NA 25 NA 744,987 29,799 
4) Pazopanib Oral 43 11 25.6 734,719 66,793 
5) Nilotinib Oral 37 4 10.8 539,329 134,832 
6) Sunitinib Oral 11 4 36.4 538,983 134,746 
7) Crizotinib Oral 13 2 15.4 519,715 259,858 
8) Sorafenib Oral 46 11 23.9 513,020 46,638 
9) Lenalidomide Oral 188 4 2.1 473,309 118,327 
10) Ipilimumab IV 26 6 23.1 465,387 77,565 
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